Japanese Patent Grant

CRISM Therapeutics Corporation

20 January 2026

 

20 January 2026

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

Japanese Patent Grant for ChemoSeed

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that it has been granted a patent (7800909) by the Japanese Patent Office. 

The patent relates to the Company's lead product, ChemoSeed®, for chemotherapeutic drug implants and more, particularly, to biodegradable chemotherapeutic drug implants comprising irinotecan.   ChemoSeed was invented by Professor Chris McConville, CRISM's Chief Scientific Officer.

The patent covers the manufacturing processes for the preparation of these chemotherapeutic drug implants and to their use in therapy, in particular in treating brain tumours such as glioblastoma. 

Commenting on the patent grant, CRISM Therapeutics' CEO, Andrew Webb, said: "We are pleased to have started 2026 by strengthening our IP position through the grant of this patent in Japan, which we view as a key market. This latest patent grant broadens our appeal to potential commercial partners.  We remain confident in CRISM's prospects for the year ahead as we prepare for our registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma."

-Ends-

Enquiries:

Company	Nomad and Broker	Financial PR
CRISM Therapeutics Corporation	S.P. Angel Corporate Finance LLP	Burson Buchanan
Andrew Webb, CEO Chris McConville, CSO	Richard Morrison Vadim Alexandre Adam Cowl	Mark Court / Jamie Hooper [e-mail]
via Burson Buchanan	[phone]	[phone]

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

CRISM will initiate its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed™ in patients with surgically resectable glioblastoma in Q1 2026.

For more information please visit: https://www.crismtherapeutics.com/

 

END